NeoGenomics Statistics
Total Valuation
NeoGenomics has a market cap or net worth of $1.33 billion. The enterprise value is $1.58 billion.
Important Dates
The last earnings date was Tuesday, February 17, 2026, before market open.
| Earnings Date | Feb 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NeoGenomics has 129.81 million shares outstanding. The number of shares has increased by 1.14% in one year.
| Current Share Class | 129.81M |
| Shares Outstanding | 129.81M |
| Shares Change (YoY) | +1.14% |
| Shares Change (QoQ) | +0.18% |
| Owned by Insiders (%) | 1.27% |
| Owned by Institutions (%) | 99.88% |
| Float | 118.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 66.00 |
| PS Ratio | 1.83 |
| Forward PS | 1.66 |
| PB Ratio | 1.58 |
| P/TBV Ratio | 51.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 254.66 |
| PEG Ratio | 2.13 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.26, with a Debt / Equity ratio of 0.49.
| Current Ratio | 4.26 |
| Quick Ratio | 3.61 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | 52.97 |
| Debt / FCF | n/a |
| Interest Coverage | -18.56 |
Financial Efficiency
Return on equity (ROE) is -12.42% and return on invested capital (ROIC) is -6.42%.
| Return on Equity (ROE) | -12.42% |
| Return on Assets (ROA) | -2.90% |
| Return on Invested Capital (ROIC) | -6.42% |
| Return on Capital Employed (ROCE) | -5.48% |
| Weighted Average Cost of Capital (WACC) | 10.08% |
| Revenue Per Employee | $330,605 |
| Profits Per Employee | -$49,102 |
| Employee Count | 2,500 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 14.95 |
Taxes
| Income Tax | -2.24M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.85% in the last 52 weeks. The beta is 1.58, so NeoGenomics's price volatility has been higher than the market average.
| Beta (5Y) | 1.58 |
| 52-Week Price Change | -28.85% |
| 50-Day Moving Average | 12.12 |
| 200-Day Moving Average | 9.15 |
| Relative Strength Index (RSI) | 29.21 |
| Average Volume (20 Days) | 1,901,478 |
Short Selling Information
| Short Interest | 10.02M |
| Short Previous Month | 8.09M |
| Short % of Shares Out | 7.72% |
| Short % of Float | 8.42% |
| Short Ratio (days to cover) | 5.12 |
Income Statement
In the last 12 months, NeoGenomics had revenue of $727.33 million and -$108.03 million in losses. Loss per share was -$0.84.
| Revenue | 727.33M |
| Gross Profit | 313.89M |
| Operating Income | -69.65M |
| Pretax Income | -110.27M |
| Net Income | -108.03M |
| EBITDA | -1.82M |
| EBIT | -69.65M |
| Loss Per Share | -$0.84 |
Full Income StatementBalance Sheet
The company has $159.62 million in cash and $409.46 million in debt, with a net cash position of -$249.84 million or -$1.92 per share.
| Cash & Cash Equivalents | 159.62M |
| Total Debt | 409.46M |
| Net Cash | -249.84M |
| Net Cash Per Share | -$1.92 |
| Equity (Book Value) | 836.56M |
| Book Value Per Share | 6.49 |
| Working Capital | 287.99M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $5.23 million and capital expenditures -$27.01 million, giving a free cash flow of -$21.78 million.
| Operating Cash Flow | 5.23M |
| Capital Expenditures | -27.01M |
| Free Cash Flow | -21.78M |
| FCF Per Share | -$0.17 |
Full Cash Flow StatementMargins
Gross margin is 43.16%, with operating and profit margins of -9.58% and -14.85%.
| Gross Margin | 43.16% |
| Operating Margin | -9.58% |
| Pretax Margin | -15.16% |
| Profit Margin | -14.85% |
| EBITDA Margin | -0.25% |
| EBIT Margin | -9.58% |
| FCF Margin | n/a |
Dividends & Yields
NeoGenomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.14% |
| Shareholder Yield | -1.14% |
| Earnings Yield | -8.11% |
| FCF Yield | -1.64% |
Analyst Forecast
The average price target for NeoGenomics is $11.50, which is 12.09% higher than the current price. The consensus rating is "Buy".
| Price Target | $11.50 |
| Price Target Difference | 12.09% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 9.88% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 16, 2003. It was a reverse split with a ratio of 1:100.
| Last Split Date | Apr 16, 2003 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
NeoGenomics has an Altman Z-Score of 1.58 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.58 |
| Piotroski F-Score | 4 |
